Fig. 3
From: Astrocyte-derived clusterin suppresses amyloid formation in vivo
Elevated CLU levels influence amyloid-associated gliosis in APP/PS1 mice. a Astrogliosis (red), determined by GFAP staining, was present in close proximity to amyloid plaques (blue) in APP/PS1 mice. Scale bar, 100 μm. b Quantification of GFAP immunoreactivity showing the significant decrease in the number of reactive astrocytes in APP/PS1AAV-CLU mice (45.44 ± 9.40) compared to controls (100 ± 21.17). N = 10 mice/group. Data are presented as mean ± S.E.M. and analyzed by Student’s t test *p < 0.05. c Real-time quantitative PCR showing a decrease in the levels of Gfap in cortex of APP/PS1AAV-CLU (0.78 ± 0.05) compared to APP/PS1AAV-GFP mice (1 ± 0.08). N = 15 mice/group. Data are presented as mean ± S.E.M. and analyzed by Student’s t test *p < 0.05. d Increased CLU expression decreases the level of microgliosis (red) associated with amyloid plaques (blue). Scale bar, 100 μm. e Quantification of IBA1 immunoreactivity presenting a reduction of microgliosis in APP/PS1AAV-CLU (68.32 ± 8.83) compared to APP/PS1AAV-GFP (100 ± 7.91). N = 10 mice/group. Data are presented as mean ± S.E.M. and analyzed by Student’s t test *p < 0.05. f RT-qPCR showing a reduction in Cst7 levels in cortex of APP/PS1AAV-CLU mice (0.65 ± 0.06) compared to APP/PS1AAV-GFP animals (1 ± 0.12). N = 15 mice/group. Data are presented as mean ± S.E.M. and analyzed by Student’s t test *p < 0.05